RT Journal Article
SR Electronic
T1 COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.29.21261312
DO 10.1101/2021.07.29.21261312
A1 Xu, Zhaowei
A1 Li, Yang
A1 Lei, Qing
A1 Huang, Likun
A1 Lai, Dan-yun
A1 Guo, Shu-juan
A1 Jiang, He-wei
A1 Hou, Hongyan
A1 Zheng, Yun-xiao
A1 Wang, Xue-ning
A1 Wu, Jiaoxiang
A1 Ma, Ming-liang
A1 Zhang, Bo
A1 Chen, Hong
A1 Yu, Caizheng
A1 Xue, Jun-biao
A1 Zhang, Hai-nan
A1 Qi, Huan
A1 Yu, Siqi
A1 Lin, Mingxi
A1 Zhang, Yandi
A1 Lin, Xiaosong
A1 Yao, Zongjie
A1 Sheng, Huiming
A1 Sun, Ziyong
A1 Wang, Feng
A1 Fan, Xionglin
A1 Tao, Sheng-ce
YR 2021
UL http://medrxiv.org/content/early/2021/08/01/2021.07.29.21261312.abstract
AB Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (COVID-ONE humoral immune). COVID-ONE humoral immunity is based on a dataset that contains the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 COVID-19 samples collected from 783 patients. In addition, 96 clinical parameters for the 2,360 samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE humoral immune provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-humoral immune is freely available at www.COVID-ONE.cn.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by the National Key Research and Development Program of China Grant (No.2016YFA0500600), National Natural Science Foundation of China (No. 31970130, 31600672, 31900112, 21907065 and 32000027).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics statement. The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (ITJ-C20200128). Written informed consent was obtained from all participants enrolled in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCOVID-ONE-humoral immune is freely accessible at www.covid-one.cn. The SARS-CoV-2 proteome microarray data are deposited on Protein Microarray Database under the accession number PMDE244 (http://www.proteinmicroarray.cn). If author need the raw data of antibody responses or clinical parameters, please contact the corresponding author (taosc{at}sjtu.edu.cn).